PledPharma seeks partner for lead therapy

Jacques Näsström, CEO of Pled Pharma, chats with Sten Stovall, senior editor at Pharma Intelligence, about the company’s current hunt for licensing partners for lead product PledOx (calmangafodipir), which is being developed as a preventative therapy against nerve damage associated with cytotoxic therapy in colorectal cancer patients. They also discuss a regulatory pathway for PledOx and development plans for the company's other pipeline assets.

[video src="https://www.youtube.com/embed/DfVHLjGbGZ0?']

Interviewer: Sten Stovall – Senior Editor, Pharma Intelligence, In Vivo/Pink Sheet/Scrip
Interviewee: Jacques Näsström – CEO, PledPharma AB